- Home >
- Clinicals Trials >
- HARMONi-3
Lung cancer
HARMONi-3
A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.
- Open at Paris since : 04/12/2024
- Target : Adult
- Phase : Phase III
Trial description
To compare overall survival (OS) between ivonescimab combined with carboplatin and paclitaxel or nab-paclitaxel versus pembrolizumab combined with carboplatin and paclitaxel or nab-paclitaxel
Url of the trialMain investigator
